{
    "id": "27n5xyu4n36dnbzdmwxqyj3daus77ezg",
    "title": "Bringing gene therapy based SOD1 silencing towards human trials: A highly efficacious, off-target free and biomarker supported strategy for fALS",
    "info": {
        "author": [
            "Joseph M. Scarrott, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield"
        ],
        "published": "July 21, 2017",
        "recorded": "May 2017",
        "category": [
            "Top->Medicine",
            "Top->Medicine->Neuroscience"
        ]
    },
    "url": "http://videolectures.net/encals2017_scarrott_gene_therapy/",
    "segmentation": [
        [
            "I'd like to teach today about the results of our study, which we believe contributes several important translational elements to what's a promising gene therapy strategy for the treatment of SOD.",
            "One links.",
            "Familial ALST.",
            "So."
        ],
        [
            "The aims of our study, we wanted to evaluate the in vivo efficacy of sod, one silencing in the sod 1G93 amaos, using a clinical ready vector.",
            "To measure the CSF sod one protein levels as a potential biomarker for effective dosing and efficacy of SOD.",
            "One knocked down in the mice.",
            "And to investigate the potential for any Micronet micro RNA like sequence specific off target effects stemming from the use of an SH RNA in vivo.",
            "So just for a little bit."
        ],
        [
            "Grounds are interference whereby small RNA molecules bind to M RNA transcripts and degrading the transcripts resulting in knockdown of protein levels has been investigated by several groups in the past by the lentiviral delivery of a short hairpin RNA and demo associated virus delivery of SH RNA.",
            "And also artificial micro knees and antisense oligonucleotides therapy which is sort of broadly work in the same the same mechanism."
        ],
        [
            "So the one of the first translates for all elements of our study is the use of a clinic ready vector, whereby we took a previously validated AAV vector expressing SH RNA under the control of the H1 promoter.",
            "We remove the nonessential Reporter construct featuring GFP and replace it with this stuff sequence made up essentially have just plasmid backbone DNA, but maintained the essential SH RNA portion in the construct."
        ],
        [
            "So to test in vivo efficacy of this construct, mice were injected either post Natal day one, which we would consider pre onset or onset posted a 40."
        ],
        [
            "Neither are therapeutic vector or a vector containing a scrambled SH RNA as a control.",
            "Most rejected by the Cisterna Magna, which we've shown in allowed previously that if you inject an AVAV 9 viral vector expressing GFP, you get widespread transduction in the CNS.",
            "Very nice translation in the cerebellum cortex, brainstem, the hippocampus and also in the motor neurons of the spinal cord."
        ],
        [
            "So the mice were evaluated based on their visible symptoms by a scoring system as shown on the right, so a higher score related to a more severe phenotype."
        ],
        [
            "And as you can see, so in blue, where is the scramble control where you see a clear progression of symptoms overtime becoming more severe, and this is ameliorated quite quite strongly with the viral vector in red."
        ],
        [
            "We also see a delay in onset of disease where we define onset as the time it takes for a 20% drop in rotarod performance of 60 three days in the viral very particular viral treated mice in red."
        ],
        [
            "We also see an improvement in motor performance.",
            "You might see you like.",
            "You'll notice there's a drop.",
            "It seems like an initial drop in recovery.",
            "What we think this actually is is the bar distribution of the virus.",
            "The better the redistribution, the better than knocked down, and the better the recovery of symptoms.",
            "So if you look on the the Kaplan Meier curve on the right.",
            "You'll see those sort of an initial group with a sooner sooner.",
            "Time of death, which we basically think correlates this initial drop in the rotor performance as well, but with the treated mice we see a 42% increase in median lifespan in the P1 treated animals."
        ],
        [
            "I've got a video, but I'm not sure how to make it work.",
            "OK, so these are two mice, both treated at P1.",
            "They're both 144 days old and you can see that there's really quite a sort of significant rescue of the phenotype in the treated mouse compared to the scramble treated control mouse.",
            "Which obviously displays far more severe phenotype.",
            "He sees it's poorly groomed a clear tremor."
        ],
        [
            "So we also see a rescue in motor neuron count quantified on the right.",
            "So this is a little stained lumbar spinal cord where we see.",
            "Yeah.",
            "Rescue in motor neuron death.",
            "I'm."
        ],
        [
            "I also see a reduction in reactive liosis in the SH RNA treated mice compared with the control where we see a reduction in staining for GFP for reactive astrocytes and also microglia which is an orange."
        ],
        [
            "For the P40 mice, we still see an amelioration in the neuro scoring, although not as significant as we see for the P1 mice as we'd expect from treating at a later time point.",
            "And we also see a improvement in rural schools as well, but also less significant than the P1 mice."
        ],
        [
            "We see a survival as well, even at the later time point of treatment of 14% increase in median survival, which is 19 days median survival."
        ],
        [
            "So for the second game, we were interested to know if we could take CSF from the mice treated with therapeutic vector and see if we can detected down regulation of protein as a potential biomarker for any future clinical trials in humans, as the sort of the removal of CSF would be a sort of fairly noninvasive method of reserves of biomarker for treatment."
        ],
        [
            "So using just a commercially available ELISA for sod one, we can see that we get a 63% decrease in sod, one protein in the CSF.",
            "So this is 4 weeks post injection in the P1 mice.",
            "So that gives us confidence that this could be potentially quite a useful biomarker in clinical trials."
        ],
        [
            "And one of the potential problems of using SN SH RNA in vivo is the potential for any off target effects.",
            "SH RNA's are designed to be perfectly complementary to the target M RNA, but they can potentially act like indulgence.",
            "Micro RNAs, whereby the seed sequence the first 2 to 7 nucleotides, the SH RNA sequence can potentially bind."
        ],
        [
            "Some multiple transcripts.",
            "I'm on my transcripts in their free prime UTR often contain seed sequences for the micro RNA's and if the SH RNA used therapy contains a seed sequence that matches even indulges micro RNA or a widely represented seed sequence in the three prime UTR own we could.",
            "Potentially expect to see.",
            "Off target gene gene downregulation.",
            "Instead of just our target Gene."
        ],
        [
            "So one way we could potentially or how we potentially looked at whether this was the case.",
            "If you mutates the central portion of your SH RNA to their complementary base pairs, you abolish its on, targeting downregulation of.",
            "In our case, sod one so for our normal therapeutic SH RNA, we expect it to bind perfectly.",
            "We see knockdown of M RNA in a down regulation of sod 1M RNA.",
            "If we mutate the central portion, we abolish that knock down.",
            "I know if we look at an off target M RNA we would get the we would see binding of the seed region to the seed region in the three prime UTR.",
            "Oh, and we'd maintain this seed sequence off target binding.",
            "Even with the presence of our mutated central portion of the SH RNA, so by looking at the the patterns of gene expression, we can see if any.",
            "Off target gene expression is based on the.",
            "See sequence binding, or if it's potentially downregulation based on the downstream effects of knocking down side one.",
            "So looking at."
        ],
        [
            "Whole Gina, my cronies obviously.",
            "So for the we basically created for constructs of our original therapeutic constructs with particular sequence, an unrelated SH sod, one that targets odd one, but it's a completely different seed region.",
            "A mismatch control with the same seed region is our therapeutic constructs, but that does not target side one and a negative promoter.",
            "Only virus control and the graph on the right just to show that we see knockdown of sod one in the two constructs that we expect it to, but we don't in the mismatch control or the negative control.",
            "So looking at."
        ],
        [
            "Whole genomic arrays of gene expression.",
            "We see that between our therapeutic vector and the unrelated SH sod one against sod 1M RNA, the only differentially expressed significant gene is sod one.",
            "We don't see any shared downregulated genes between our mismatch control containing the same seed sequence and our therapeutic vector.",
            "So we hope that.",
            "Really suggests that we're not seeing any sort of widespread off target gene expression from our therapeutic vector.",
            "And the PCA plot.",
            "We also don't see any sort of colocalization between the two.",
            "Therapeutic vector or the mismatch control?",
            "So."
        ],
        [
            "In summary, the clinic ready vector is effective at prolong lifespan and ameliorating disease in a mouse model of a less.",
            "The therapeutic SH RNA appears to be specific to sold one M RNA with no noticeable sequence specific off target effects and the measurement of sold one depletion in the CSF of treated patients may be a simple and effective biomarker of treatment efficacy."
        ],
        [
            "So I'd like to acknowledge my my supervisors versus Museus investigating, publish or to mass of unity in the encoded will the in vivo mouse study work?",
            "Everybody in these large group and the Kasper Group in Ohio for developing the virus and thank."
        ],
        [
            "How much will listen?"
        ]
    ],
    "summarization": {
        "clip_0": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "I'd like to teach today about the results of our study, which we believe contributes several important translational elements to what's a promising gene therapy strategy for the treatment of SOD.",
                    "label": 0
                },
                {
                    "sent": "One links.",
                    "label": 0
                },
                {
                    "sent": "Familial ALST.",
                    "label": 0
                },
                {
                    "sent": "So.",
                    "label": 0
                }
            ]
        },
        "clip_1": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "The aims of our study, we wanted to evaluate the in vivo efficacy of sod, one silencing in the sod 1G93 amaos, using a clinical ready vector.",
                    "label": 1
                },
                {
                    "sent": "To measure the CSF sod one protein levels as a potential biomarker for effective dosing and efficacy of SOD.",
                    "label": 0
                },
                {
                    "sent": "One knocked down in the mice.",
                    "label": 0
                },
                {
                    "sent": "And to investigate the potential for any Micronet micro RNA like sequence specific off target effects stemming from the use of an SH RNA in vivo.",
                    "label": 0
                },
                {
                    "sent": "So just for a little bit.",
                    "label": 0
                }
            ]
        },
        "clip_2": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Grounds are interference whereby small RNA molecules bind to M RNA transcripts and degrading the transcripts resulting in knockdown of protein levels has been investigated by several groups in the past by the lentiviral delivery of a short hairpin RNA and demo associated virus delivery of SH RNA.",
                    "label": 0
                },
                {
                    "sent": "And also artificial micro knees and antisense oligonucleotides therapy which is sort of broadly work in the same the same mechanism.",
                    "label": 0
                }
            ]
        },
        "clip_3": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So the one of the first translates for all elements of our study is the use of a clinic ready vector, whereby we took a previously validated AAV vector expressing SH RNA under the control of the H1 promoter.",
                    "label": 0
                },
                {
                    "sent": "We remove the nonessential Reporter construct featuring GFP and replace it with this stuff sequence made up essentially have just plasmid backbone DNA, but maintained the essential SH RNA portion in the construct.",
                    "label": 0
                }
            ]
        },
        "clip_4": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So to test in vivo efficacy of this construct, mice were injected either post Natal day one, which we would consider pre onset or onset posted a 40.",
                    "label": 0
                }
            ]
        },
        "clip_5": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Neither are therapeutic vector or a vector containing a scrambled SH RNA as a control.",
                    "label": 0
                },
                {
                    "sent": "Most rejected by the Cisterna Magna, which we've shown in allowed previously that if you inject an AVAV 9 viral vector expressing GFP, you get widespread transduction in the CNS.",
                    "label": 0
                },
                {
                    "sent": "Very nice translation in the cerebellum cortex, brainstem, the hippocampus and also in the motor neurons of the spinal cord.",
                    "label": 0
                }
            ]
        },
        "clip_6": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So the mice were evaluated based on their visible symptoms by a scoring system as shown on the right, so a higher score related to a more severe phenotype.",
                    "label": 0
                }
            ]
        },
        "clip_7": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "And as you can see, so in blue, where is the scramble control where you see a clear progression of symptoms overtime becoming more severe, and this is ameliorated quite quite strongly with the viral vector in red.",
                    "label": 0
                }
            ]
        },
        "clip_8": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "We also see a delay in onset of disease where we define onset as the time it takes for a 20% drop in rotarod performance of 60 three days in the viral very particular viral treated mice in red.",
                    "label": 0
                }
            ]
        },
        "clip_9": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "We also see an improvement in motor performance.",
                    "label": 0
                },
                {
                    "sent": "You might see you like.",
                    "label": 0
                },
                {
                    "sent": "You'll notice there's a drop.",
                    "label": 0
                },
                {
                    "sent": "It seems like an initial drop in recovery.",
                    "label": 0
                },
                {
                    "sent": "What we think this actually is is the bar distribution of the virus.",
                    "label": 0
                },
                {
                    "sent": "The better the redistribution, the better than knocked down, and the better the recovery of symptoms.",
                    "label": 0
                },
                {
                    "sent": "So if you look on the the Kaplan Meier curve on the right.",
                    "label": 0
                },
                {
                    "sent": "You'll see those sort of an initial group with a sooner sooner.",
                    "label": 0
                },
                {
                    "sent": "Time of death, which we basically think correlates this initial drop in the rotor performance as well, but with the treated mice we see a 42% increase in median lifespan in the P1 treated animals.",
                    "label": 0
                }
            ]
        },
        "clip_10": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "I've got a video, but I'm not sure how to make it work.",
                    "label": 0
                },
                {
                    "sent": "OK, so these are two mice, both treated at P1.",
                    "label": 0
                },
                {
                    "sent": "They're both 144 days old and you can see that there's really quite a sort of significant rescue of the phenotype in the treated mouse compared to the scramble treated control mouse.",
                    "label": 1
                },
                {
                    "sent": "Which obviously displays far more severe phenotype.",
                    "label": 0
                },
                {
                    "sent": "He sees it's poorly groomed a clear tremor.",
                    "label": 0
                }
            ]
        },
        "clip_11": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So we also see a rescue in motor neuron count quantified on the right.",
                    "label": 0
                },
                {
                    "sent": "So this is a little stained lumbar spinal cord where we see.",
                    "label": 0
                },
                {
                    "sent": "Yeah.",
                    "label": 0
                },
                {
                    "sent": "Rescue in motor neuron death.",
                    "label": 0
                },
                {
                    "sent": "I'm.",
                    "label": 0
                }
            ]
        },
        "clip_12": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "I also see a reduction in reactive liosis in the SH RNA treated mice compared with the control where we see a reduction in staining for GFP for reactive astrocytes and also microglia which is an orange.",
                    "label": 0
                }
            ]
        },
        "clip_13": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "For the P40 mice, we still see an amelioration in the neuro scoring, although not as significant as we see for the P1 mice as we'd expect from treating at a later time point.",
                    "label": 0
                },
                {
                    "sent": "And we also see a improvement in rural schools as well, but also less significant than the P1 mice.",
                    "label": 0
                }
            ]
        },
        "clip_14": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "We see a survival as well, even at the later time point of treatment of 14% increase in median survival, which is 19 days median survival.",
                    "label": 0
                }
            ]
        },
        "clip_15": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So for the second game, we were interested to know if we could take CSF from the mice treated with therapeutic vector and see if we can detected down regulation of protein as a potential biomarker for any future clinical trials in humans, as the sort of the removal of CSF would be a sort of fairly noninvasive method of reserves of biomarker for treatment.",
                    "label": 0
                }
            ]
        },
        "clip_16": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So using just a commercially available ELISA for sod one, we can see that we get a 63% decrease in sod, one protein in the CSF.",
                    "label": 0
                },
                {
                    "sent": "So this is 4 weeks post injection in the P1 mice.",
                    "label": 0
                },
                {
                    "sent": "So that gives us confidence that this could be potentially quite a useful biomarker in clinical trials.",
                    "label": 0
                }
            ]
        },
        "clip_17": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "And one of the potential problems of using SN SH RNA in vivo is the potential for any off target effects.",
                    "label": 1
                },
                {
                    "sent": "SH RNA's are designed to be perfectly complementary to the target M RNA, but they can potentially act like indulgence.",
                    "label": 0
                },
                {
                    "sent": "Micro RNAs, whereby the seed sequence the first 2 to 7 nucleotides, the SH RNA sequence can potentially bind.",
                    "label": 0
                }
            ]
        },
        "clip_18": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Some multiple transcripts.",
                    "label": 0
                },
                {
                    "sent": "I'm on my transcripts in their free prime UTR often contain seed sequences for the micro RNA's and if the SH RNA used therapy contains a seed sequence that matches even indulges micro RNA or a widely represented seed sequence in the three prime UTR own we could.",
                    "label": 0
                },
                {
                    "sent": "Potentially expect to see.",
                    "label": 0
                },
                {
                    "sent": "Off target gene gene downregulation.",
                    "label": 0
                },
                {
                    "sent": "Instead of just our target Gene.",
                    "label": 0
                }
            ]
        },
        "clip_19": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So one way we could potentially or how we potentially looked at whether this was the case.",
                    "label": 0
                },
                {
                    "sent": "If you mutates the central portion of your SH RNA to their complementary base pairs, you abolish its on, targeting downregulation of.",
                    "label": 0
                },
                {
                    "sent": "In our case, sod one so for our normal therapeutic SH RNA, we expect it to bind perfectly.",
                    "label": 0
                },
                {
                    "sent": "We see knockdown of M RNA in a down regulation of sod 1M RNA.",
                    "label": 0
                },
                {
                    "sent": "If we mutate the central portion, we abolish that knock down.",
                    "label": 0
                },
                {
                    "sent": "I know if we look at an off target M RNA we would get the we would see binding of the seed region to the seed region in the three prime UTR.",
                    "label": 0
                },
                {
                    "sent": "Oh, and we'd maintain this seed sequence off target binding.",
                    "label": 0
                },
                {
                    "sent": "Even with the presence of our mutated central portion of the SH RNA, so by looking at the the patterns of gene expression, we can see if any.",
                    "label": 0
                },
                {
                    "sent": "Off target gene expression is based on the.",
                    "label": 0
                },
                {
                    "sent": "See sequence binding, or if it's potentially downregulation based on the downstream effects of knocking down side one.",
                    "label": 0
                },
                {
                    "sent": "So looking at.",
                    "label": 0
                }
            ]
        },
        "clip_20": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "Whole Gina, my cronies obviously.",
                    "label": 0
                },
                {
                    "sent": "So for the we basically created for constructs of our original therapeutic constructs with particular sequence, an unrelated SH sod, one that targets odd one, but it's a completely different seed region.",
                    "label": 0
                },
                {
                    "sent": "A mismatch control with the same seed region is our therapeutic constructs, but that does not target side one and a negative promoter.",
                    "label": 0
                },
                {
                    "sent": "Only virus control and the graph on the right just to show that we see knockdown of sod one in the two constructs that we expect it to, but we don't in the mismatch control or the negative control.",
                    "label": 0
                },
                {
                    "sent": "So looking at.",
                    "label": 0
                }
            ]
        },
        "clip_21": {
            "is_summarization_sample": true,
            "summarization_data": [
                {
                    "sent": "Whole genomic arrays of gene expression.",
                    "label": 0
                },
                {
                    "sent": "We see that between our therapeutic vector and the unrelated SH sod one against sod 1M RNA, the only differentially expressed significant gene is sod one.",
                    "label": 0
                },
                {
                    "sent": "We don't see any shared downregulated genes between our mismatch control containing the same seed sequence and our therapeutic vector.",
                    "label": 1
                },
                {
                    "sent": "So we hope that.",
                    "label": 0
                },
                {
                    "sent": "Really suggests that we're not seeing any sort of widespread off target gene expression from our therapeutic vector.",
                    "label": 0
                },
                {
                    "sent": "And the PCA plot.",
                    "label": 0
                },
                {
                    "sent": "We also don't see any sort of colocalization between the two.",
                    "label": 0
                },
                {
                    "sent": "Therapeutic vector or the mismatch control?",
                    "label": 0
                },
                {
                    "sent": "So.",
                    "label": 0
                }
            ]
        },
        "clip_22": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "In summary, the clinic ready vector is effective at prolong lifespan and ameliorating disease in a mouse model of a less.",
                    "label": 0
                },
                {
                    "sent": "The therapeutic SH RNA appears to be specific to sold one M RNA with no noticeable sequence specific off target effects and the measurement of sold one depletion in the CSF of treated patients may be a simple and effective biomarker of treatment efficacy.",
                    "label": 0
                }
            ]
        },
        "clip_23": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "So I'd like to acknowledge my my supervisors versus Museus investigating, publish or to mass of unity in the encoded will the in vivo mouse study work?",
                    "label": 0
                },
                {
                    "sent": "Everybody in these large group and the Kasper Group in Ohio for developing the virus and thank.",
                    "label": 0
                }
            ]
        },
        "clip_24": {
            "is_summarization_sample": false,
            "summarization_data": [
                {
                    "sent": "How much will listen?",
                    "label": 0
                }
            ]
        }
    }
}